Cybrexa Therapeutics
Mike Needle has a strong background in the medical field, with extensive work experience in various leadership roles. Mike is currently the Chief Medical Officer at Cybrexa Therapeutics, a position they have held since December 2022. Prior to their current role, Mike served as the Chief Medical Officer at AVEO Oncology from January 2015 to November 2021.
Before joining AVEO Oncology, Mike worked at Array BioPharma as the Chief Medical Officer from April 2013 to September 2014. Mike also held the same position at the Multiple Myeloma Research Foundation from April 2012 to March 2013.
In addition, Mike has an academic background and served as an Assistant Professor of Clinical Pediatrics at Columbia University Medical Center from May 2010 to March 2013. Mike has also had significant experience in the pharmaceutical industry, including roles at Celgene (2004-2010), where they played a key role in starting the phase IV/medical affairs program in oncology, and at ImClone (2000-2004), where they grew the clinical affairs department.
Mike'searlier work experiences include being a Director at Searle from 1997 to 2000 and an Assistant Professor of Pediatrics at the University of Pennsylvania / CHOP from July 1993 to November 1997.
Overall, Mike Needle has extensive experience in leadership positions within the medical field, bringing valuable expertise to their role as Chief Medical Officer at Cybrexa Therapeutics.
Mike Needle earned their Bachelor of Arts degree in Physics from Binghamton University, where they attended from 1977 to 1981. Mike then pursued further education at the State University of New York Downstate Health Sciences University from 1981 to 1985, where they obtained their Doctor of Medicine (MD) degree.
This person is not in any offices
Cybrexa Therapeutics
1 followers
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.